COST-EFFECTIVENESS OF OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR FOR PATIENTS WITH CHRONIC HCV IN THE NETHERLANDS

被引：1
|
作者：
Gaultney, J. [1 ]
de Knegt, R. J. [2 ]
Fassler, P. [3 ]
Visser, S. [3 ]
Johnson, S. [4 ]
机构：
[1] Mapi Grp, Houten, Netherlands
[2] Erasmus MC, Rotterdam, Netherlands
[3] AbbVie BV, Hoofddorp, Netherlands
[4] Medicus Econ LLC, Milton, MA USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.1504
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN71
引用
收藏
页码：A588 / A588
页数：1
相关论文
共 50 条
  • [1] OMBITASVIR/PARITAPREVIR/RITONAVIR PLUS DASABUVIR TREATMENT EXPERIENCE IN HCV PATIENTS
    Bayan, Kadim
    Celen, Mustafa Kemal
    Dal, Tuba
    Ayaz, Celal
    Tekin, Recep
    Akdemir, Irem
    Sari, Tugba
    Gunal, Ozgur
    Efe, Savas Cumali
    ACTA MEDICA MEDITERRANEA, 2018, 34 (01): : 71 - 75
  • [2] Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis
    Jingjing Wu
    Peng Huang
    Haozhi Fan
    Ting Tian
    Xueshan Xia
    Zuqiang Fu
    Yan Wang
    Xiangyu Ye
    Ming Yue
    Yun Zhang
    Virology Journal, 16
  • [3] Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis
    Wu, Jingjing
    Huang, Peng
    Fan, Haozhi
    Tian, Ting
    Xia, Xueshan
    Fu, Zuqiang
    Wang, Yan
    Ye, Xiangyu
    Yue, Ming
    Zhang, Yun
    VIROLOGY JOURNAL, 2019, 16
  • [4] COST PER PATIENT WITH SUSTAINED VIRAL RESPONSE FOR OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR WITH OR WITHOUT RIBAVARIN IN GENOTYPE 1 PATIENTS WITH CHRONIC HCV IN THE NETHERLANDS
    Gaultney, J.
    de Knegt, R. J.
    Fassler, P.
    Visser, S.
    Johnson, S.
    VALUE IN HEALTH, 2015, 18 (07) : A586 - A586
  • [5] Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection
    Lucejko, Mariusz
    Parfieniuk-Kowerda, Anna
    Flisiak, Robert
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (08) : 1153 - 1164
  • [6] COST-EFFECTIVENESS OF PARITAPREVIR/ROTANAVIR/OMBITASVIR WITH OR WITHOUT DASABUVIR IN IRELAND
    Baj, R.
    Kavanagh, J.
    Egan, K. M.
    McKinley, C.
    VALUE IN HEALTH, 2016, 19 (07) : A512 - A512
  • [7] COST-EFFECTIVENESS OF OMBITASVIR/PARITAPREVIR/RITONAVIR WITH OR WITHOUT DASABUVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C PATIENTS INFECTED WITH GENOTYPE 1 OR 4 IN FRANCE
    Sroczynski, G.
    Conrads-Frank, A.
    Muhlberger, N.
    Kuhne, F.
    Jeanblanc, G.
    Samp, J. C.
    Durand-Zaleski, I
    Siebert, U.
    VALUE IN HEALTH, 2016, 19 (07) : A416 - A416
  • [8] Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection
    Emma D. Deeks
    Drugs, 2015, 75 : 1027 - 1038
  • [9] Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir plus Ribavirin for US Post-Liver Transplant Recurrent Genotype 1 HCV
    Saab, Sammy
    Gonzalez, Yuri S.
    Huber, Caroline
    Wang, Alice
    Juday, Timothy
    LIVER INTERNATIONAL, 2016, 36 (04) : 515 - 521
  • [10] Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection
    Deeks, Emma D.
    DRUGS, 2015, 75 (09) : 1027 - 1038
12345